STEPHANIE DOMBROWSKI: Open Payments
NPI 1649963653 · MARLTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$512 in 21 payments from 7 companies in 2025. Trend: 2023 $136 · 2024 $621 · 2025 $512
Food & beverage: $512
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $180 |
| E.R. Squibb & Sons, L.L.C. | 2 | $131 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Axsome Therapeutics, Inc. | 4 | $66 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Neurocrine BioSciences, Inc. | 1 | $17 |
Products named: VRAYLAR, COBENFY, REXULTI, Auvelity, Qelbree, TRINTELLIX, INGREZZA.
Industry payments across NJ — which companies pay providers there.
